Proportion of Subjects Achieving a Molluscum Lesion Count of 0 or 1 at the Day 84 End of Study Visit in Phase 3 Clinical Trials With VP-102 CAMP-1 and CAMP-2. J of Skin 2021, 5 (6), s92. https://doi.org/10.25251/skin.5.supp.92.